Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M. Stumvoll, J. Gerich.
Clinical features of insulin resistance and beta cell dysfunction and the relationship to type 2 diabetes.
Clin Lab Med, 21 (2001), pp. 31-51
[2.]
R.N. Bergman, R. Prager, A. Volund, J.M. Olefsky.
Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp.
J Clin Invest, 79 (1987), pp. 790-800
[3.]
R.A. De Fronzo, J.D. Tobin, R. Andres.
Glucose clamp tecnique: a method for quantifying insulin secretion and resistance.
Am J Physiol, (1979), pp. E214-E222
[4.]
G. Boden, F. Jadali, J.V. White, Y. Liang, M. Mozzoli, X. Chen, et al.
Effects of fat on insulin-stimulated carbohydrate metabolism in normal men.
J Clin Invest, 88 (1991), pp. 960-966
[5.]
C. Beysen, F. Karpe, B.A. Fielding, A. Clark, J.C. Levy, K.N. Frayn.
Interaction between specific fatty acids, GLP-1 and insulin secretion in humans.
Diabetologia, 45 (2002), pp. 1533-1541
[6.]
H. Hirose, Y.H. lee, L.R. Inman, Y. Nagasawa, J.H. Johnson, R.H. Unger.
Defective fatty acid-mediated beta-cell compensation in Zucker diabetic fatty rats. Pathogenic implications for obesity-dependent diabetes.
J Biol Chem, 271 (1996), pp. 5633-5637
[7.]
G. Paolisso, M. Barbagallo, G. Petrella, E. Ragno, M. Barbieri, M. Giordano, et al.
Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients.
Atherosclerosis, (2000), pp. 121-127
[8.]
D.C. Chan, G.F. Watts, P.H.R. Barrett, L.J. Beilin, T.G. Redgrave, T.A. Mori.
Regulatory effects of HMG-CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.
Diabetes, 51 (2002), pp. 2377-2386
[9.]
B. Staells, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, J.C. Fruchart.
Mechanism of action of fibrates on lipid and lipoprotein metabolism.
Circulation, 98 (1998), pp. 2088-2093
[10.]
D. Zambón, E. Ros, C. Rodríguez-Villar, J.C. Laguna, M. Vázquez, C. Sanllehy, et al.
Randomized crossover study of gemfibrozil vs lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid reulation.
Metabolism, 48 (1999), pp. 47-54
[11.]
R. Goldberg, P. La Belle, R. Zupkis, P. Ronca.
Comparison of the effect of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus.
Am J Cardiol, 66 (1990), pp. 16B-21B
[12.]
A.M. Wägner, O. Jorba, E. Bonet, J. Ordoñez-Llamas, A. Pérez.
Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia.
J Clin Endocrinol Metab, 88 (2003), pp. 3212-3217
[13.]
T. Jeck, W.F. Riesen, U. Keller.
Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.
Diabet Med, 14 (1997), pp. 564-570
[14.]
D.A. Winegar, P.J. Brown, W.O. Wilkison, M.C. Lewis, R.J. Ott, W.Q. Tong, et al.
Effects of fenofibrate on lipid parameters in obese rhesus monkeys.
J Lipid Res, 42 (2001), pp. 1543-1551
[15.]
H.J. Lee, S.S. Choi, M.K. Park, Y.J. An, S.Y. Seo, M.C. Kim, et al.
Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sesitivity in OLEFT rats.
Biochem Biophys Res Commun, 296 (2002), pp. 293-299
[16.]
L. Mussoni, L. Mannuci, C. Sirtori, F. Pazzucconi, G. Bonfardeci, C. Cimminiello, et al.
Effect of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients.
Atherosclerosis, 148 (2000), pp. 397-406
[17.]
D.C. Whitelaw, J.M. Smith, M. Nattrass.
Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridemia.
Diabetes Obes Metab, 4 (2002), pp. 187-194
[18.]
M. Öhrvall, H. Lithell, J. Johansson, B. Vessby.
A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia.
Metabolism, 44 (1995), pp. 212-217
[19.]
M.W. Stewart, R.G. Dyer, K.G. Alberti, M.F. Laker.
The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hiperlipidaemia.
Diabet Med, 12 (1994), pp. 250-257
[20.]
S. Ogawa, K. Takeuchi, K. Sugimura, M. Fukuda, R. Lee, S. Ito, et al.
Bezafibrate reduces blood glucose in type 2 diabetes mellitus.
Metabolism, 49 (2000), pp. 331-334
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.